A detailed history of Erste Asset Management Gmb H transactions in Argenx Se stock. As of the latest transaction made, Erste Asset Management Gmb H holds 16,800 shares of ARGX stock, worth $10.9 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
16,800
Holding current value
$10.9 Million
% of portfolio
0.11%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $7.29 Million - $9.27 Million
16,800 New
16,800 $9.01 Billion
Q3 2023

Nov 26, 2024

BUY
$369.35 - $548.43 $2.95 Million - $4.39 Million
8,000 Added 90.91%
16,800 $8.16 Billion
Q1 2023

Nov 26, 2024

BUY
$334.23 - $403.65 $568,191 - $686,205
1,700 Added 23.94%
8,800 $3.25 Billion
Q4 2022

Nov 26, 2024

BUY
$342.17 - $402.31 $581,689 - $683,927
1,700 Added 23.94%
8,800 $3.31 Billion
Q3 2022

Nov 26, 2024

SELL
$343.2 - $395.75 $3.33 Million - $3.84 Million
-9,700 Reduced 57.74%
7,100 $2.54 Billion
Q2 2022

Nov 26, 2024

SELL
$269.58 - $378.88 $2.61 Million - $3.68 Million
-9,700 Reduced 57.74%
7,100 $2.65 Billion
Q4 2021

Nov 22, 2024

SELL
$272.01 - $353.03 $2.8 Million - $3.64 Million
-10,300 Reduced 61.31%
6,500 $2.28 Billion
Q4 2020

Nov 22, 2024

SELL
$248.13 - $308.36 $1.49 Million - $1.85 Million
-6,000 Reduced 48.0%
6,500 $1.97 Billion
Q3 2020

Nov 22, 2024

SELL
$215.51 - $272.51 $926,693 - $1.17 Million
-4,300 Reduced 25.6%
12,500 $3.25 Billion
Q4 2019

Nov 22, 2024

SELL
$106.59 - $164.21 $458,337 - $706,103
-4,300 Reduced 25.6%
12,500 $2.01 Billion
Q1 2019

Nov 22, 2024

SELL
$98.85 - $134.59 $425,055 - $578,737
-4,300 Reduced 25.6%
12,500 $1.56 Billion

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $35.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.